IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages

  • Front Immunol. 2017 Mar 6;8:210. doi: 10.3389/fimmu.2017.00210.
Xu Wang  1 He Wang  1 Man-Qing Liu  2 Jie-Liang Li  1 Run-Hong Zhou  1 Yu Zhou  1 Yi-Zhong Wang  1 Wang Zhou  2 Wen-Zhe Ho  3
Affiliations
  • 1. Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine , Philadelphia, PA , USA.
  • 2. Wuhan Center for Disease Prevention and Control , Wuhan , China.
  • 3. Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA; Wuhan University School of Basic Medical Sciences, Wuhan, China.
Abstract

Type III interferons (IFN-λs) have been demonstrated to inhibit a number of viruses, including HIV. Here, we further examined the anti-HIV effect of IFN-λs in macrophages. We found that IFN-λs synergistically enhanced anti-HIV activity of antiretrovirals [azidothymidine (AZT), efavirenz, indinavir, and enfuvirtide] in infected macrophages. Importantly, IFN-λs could suppress HIV Infection of macrophages with the drug-resistant strains, including AZT-resistant virus (A012) and Reverse Transcriptase inhibitor-resistant virus (TC49). Mechanistically, IFN-λs were able to induce the expression of several important anti-HIV cellular factors, including myxovirus resistance 2 (Mx2), a newly identified HIV post-entry inhibitor and tetherin, a restriction factor that blocks HIV release from infected cells. These observations provide additional evidence to support the potential use of IFN-λs as therapeutics agents for the treatment of HIV Infection.

Keywords
IFN-λ; Mx2; antiretrovirals; drug-resistant HIV; tetherin.
Products